How do you manage atopic dermatitis in patients who have failed dupilumab?   

I like the idea of Nemluvio, because there is good data on effectiveness, there is little risk of serious side effects, dosing is q 4 weeks and can move to q 8 weeks and lower dose, there is no monitoring required, and med is given SC.